Clinical Study of Spectral CT Verida

August 10, 2026 updated by: Philips Clinical & Medical Affairs Global

Prospective, Single-Center Evaluation of Image Quality for Low-Dose Scans With Spectral Precise Image (SPI) Intelligent Denoising Versus iDose4 Reconstructions for Low- and Standard-Dose Scans - Clinical Study Protocol

This study will prospective enroll 80 subjects to evaluate the comparison of image quality, proportion of high-quality images, and image noise between the Spectral Precise Image (SPI) intelligent denoising for low-dose scans on the Spectral CT Verida system and iDose4 reconstructions after low-dose and routine-dose scans.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Shandong
      • Jinan, Shandong, China, 250011

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18 ≤ age ≤ 75 years.
  • 18 kg/m² ≤ BMI ≤ 28 kg/m².
  • Conscious, able to cooperate, and competent to perform study procedures. Voluntarily agrees to participate in this clinical study and has signed the informed consent form.
  • Women of childbearing potential must have a negative pregnancy test and have no plans to become pregnant during the next 6 months.

Exclusion Criteria:

  • Persons without full civil capacity.
  • Pregnant or breastfeeding women.
  • Any other conditions that, in the investigator's judgment, make the subject unsuitable for participation in this clinical study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low dose
Radiation: CT Radiation Scan
Use investigated CT do radiation scan
Other: Normal Dose
Radiation: CT Radiation Scan
Use investigated CT do radiation scan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The rate of good-excellent scores ≥3
Time Frame: From date of image reconstruction until the date of image reading completion, anticipated 1Week.
Image quality will be assessed by 2 radiologists using Likert-scale on a range from 1(poor) to 5(Excellent),and calculate the rate of ≥3 with FAS,PSS SS as the datasets analysis.
From date of image reconstruction until the date of image reading completion, anticipated 1Week.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective outcome:Image Noise
Time Frame: From Image reconstruction to image noise recording finished，estimate 1Week.
Will use FAS,PSS,SS do the image noise (parameters record)datasets analysis.
From Image reconstruction to image noise recording finished，estimate 1Week.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Philips Clinical & Medical Affairs Global

Collaborators

Qilu Hospital of Shandong University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 30, 2026

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2027

Study Registration Dates

First Submitted

August 3, 2026

First Submitted That Met QC Criteria

August 10, 2026

First Posted (Actual)

August 11, 2026

Study Record Updates

Last Update Posted (Actual)

August 11, 2026

Last Update Submitted That Met QC Criteria

August 10, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SEF-2025-301637

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Sponsor and site need further discuss.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe